Home > Journals > Minerva Cardiology and Angiology > Past Issues > Minerva Cardiology and Angiology 2023 June;71(3) > Minerva Cardiology and Angiology 2023 June;71(3):349-58



Publishing options
To subscribe PROMO
Submit an article
Recommend to your librarian


Publication history
Cite this article as



Minerva Cardiology and Angiology 2023 June;71(3):349-58

DOI: 10.23736/S2724-5683.22.06039-2


language: English

Rationale and design of the sirolimus eluting balloon utilization for treatment of vasculogenic erectile dysfunction: the SUASION Registry

Andrea MATTEUCCI , Daniela BENEDETTO, Michela BONANNI, Gianluca MASSARO, Debora RUSSO, Giulio RUSSO, Gaetano CHIRICOLO, Giuseppe BIONDI-ZOCCAI, Giuseppe SANGIORGI

Division of Cardiology, Policlinico Tor Vergata, University of Rome, Rome, Italy

BACKGROUND: Conventional angioplasty balloon catheter, drug coated balloon (DCB), or angioplasty with drug eluting stent (DES) have been used on the percutaneous treatment of erectile dysfunction (ED). Currently available DCBs are paclitaxel eluting balloon (PEB), very recently, sirolimus eluting balloon (SEB). Although endovascular revascularization with balloon resulted in improvement of ED, there have been no prior reports on the feasibility of SEB treatment for ED.
METHODS: We present an observational, retrospective-prospective multicentre registry in patients evaluating the use of SEB for the treatment of de novo stenosis in native internal pudendal arteries. We will include 100 patients affected by vasculogenic ED non responder to PDE5i with up to two lesions requiring treatment. ED patients should present a IIEF-5 Score<15, positive dynamic doppler (PSV <25 cm/s) and/or evidence at basal CT angiography. At 30 days, 180, 240, and 365 days following the index procedure, IIEF-5 score will be assessed, and medication regimen and adverse event monitoring will be assessed. At 8 months a dynamic Doppler will be performed. Patients will be followed up for 2 years. The primary endpoints are the Delta IIEF-5 Score and a Delta PSV between basal and 8 months follow-up. The secondary endpoint is the incidence of major adverse event (MAE), binary restenosis and late loss in patients who will repeat control angiography if clinically indicated.
CONCLUSIONS: Considering the limitations and safety concerns of PEB, POBA and DES used so far in ED clinical investigations, we hypothesize that sirolimus nanocarriers-coated balloon can potentially be an improved next-generation treatment for ED patients.

KEY WORDS: Erectile dysfunction; Sirolimus; Drug-eluting stents

top of page